Read More

Nano-Cap Eledon Pharmaceuticals’ Investigational Drug Shows Safety In Early Organ Transplant Study, Analyst Boosts Forecast On Increased Confidence

Eledon Pharmaceuticals' results from islet cell transplant trial for type 1 diabetes, with tegoprubart showing safety and efficacy in kidney transplant patients. Analysts anticipate significant advancements, reflecting in raised price targets.

ELDN

Read More

Dental Supplies Distributor Henry Schein’s Tech Segment Provides Some Stability In Challenging Macro Times: Analyst

Henry Schein reports Q1 adjusted EPS at $1.10, down 9% Y/Y, with sales at $3.17 billion, up 3.7%. Guidance projects 2024 sales growth at 8%-10%, reaffirming adjusted EPS guidance of $5.00-$5.16. William Blair attributes the EPS beat to margin expansion driven by technology and value-added services.

HSIC